Cargando…
Phase separation of FSP1 promotes ferroptosis
Ferroptosis is evolving as a highly promising approach to combat difficult-to-treat tumour entities including therapy-refractory and dedifferentiating cancers(1–3). Recently, ferroptosis suppressor protein-1 (FSP1), along with extramitochondrial ubiquinone or exogenous vitamin K and NAD(P)H/H(+) as...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338336/ https://www.ncbi.nlm.nih.gov/pubmed/37380771 http://dx.doi.org/10.1038/s41586-023-06255-6 |
_version_ | 1785071606625730560 |
---|---|
author | Nakamura, Toshitaka Hipp, Clara Santos Dias Mourão, André Borggräfe, Jan Aldrovandi, Maceler Henkelmann, Bernhard Wanninger, Jonas Mishima, Eikan Lytton, Elena Emler, David Proneth, Bettina Sattler, Michael Conrad, Marcus |
author_facet | Nakamura, Toshitaka Hipp, Clara Santos Dias Mourão, André Borggräfe, Jan Aldrovandi, Maceler Henkelmann, Bernhard Wanninger, Jonas Mishima, Eikan Lytton, Elena Emler, David Proneth, Bettina Sattler, Michael Conrad, Marcus |
author_sort | Nakamura, Toshitaka |
collection | PubMed |
description | Ferroptosis is evolving as a highly promising approach to combat difficult-to-treat tumour entities including therapy-refractory and dedifferentiating cancers(1–3). Recently, ferroptosis suppressor protein-1 (FSP1), along with extramitochondrial ubiquinone or exogenous vitamin K and NAD(P)H/H(+) as an electron donor, has been identified as the second ferroptosis-suppressing system, which efficiently prevents lipid peroxidation independently of the cyst(e)ine–glutathione (GSH)–glutathione peroxidase 4 (GPX4) axis(4–6). To develop FSP1 inhibitors as next-generation therapeutic ferroptosis inducers, here we performed a small molecule library screen and identified the compound class of 3-phenylquinazolinones (represented by icFSP1) as potent FSP1 inhibitors. We show that icFSP1, unlike iFSP1, the first described on-target FSP1 inhibitor(5), does not competitively inhibit FSP1 enzyme activity, but instead triggers subcellular relocalization of FSP1 from the membrane and FSP1 condensation before ferroptosis induction, in synergism with GPX4 inhibition. icFSP1-induced FSP1 condensates show droplet-like properties consistent with phase separation, an emerging and widespread mechanism to modulate biological activity(7). N-terminal myristoylation, distinct amino acid residues and intrinsically disordered, low-complexity regions in FSP1 were identified to be essential for FSP1-dependent phase separation in cells and in vitro. We further demonstrate that icFSP1 impairs tumour growth and induces FSP1 condensates in tumours in vivo. Hence, our results suggest that icFSP1 exhibits a unique mechanism of action and synergizes with ferroptosis-inducing agents to potentiate the ferroptotic cell death response, thus providing a rationale for targeting FSP1-dependent phase separation as an efficient anti-cancer therapy. |
format | Online Article Text |
id | pubmed-10338336 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-103383362023-07-14 Phase separation of FSP1 promotes ferroptosis Nakamura, Toshitaka Hipp, Clara Santos Dias Mourão, André Borggräfe, Jan Aldrovandi, Maceler Henkelmann, Bernhard Wanninger, Jonas Mishima, Eikan Lytton, Elena Emler, David Proneth, Bettina Sattler, Michael Conrad, Marcus Nature Article Ferroptosis is evolving as a highly promising approach to combat difficult-to-treat tumour entities including therapy-refractory and dedifferentiating cancers(1–3). Recently, ferroptosis suppressor protein-1 (FSP1), along with extramitochondrial ubiquinone or exogenous vitamin K and NAD(P)H/H(+) as an electron donor, has been identified as the second ferroptosis-suppressing system, which efficiently prevents lipid peroxidation independently of the cyst(e)ine–glutathione (GSH)–glutathione peroxidase 4 (GPX4) axis(4–6). To develop FSP1 inhibitors as next-generation therapeutic ferroptosis inducers, here we performed a small molecule library screen and identified the compound class of 3-phenylquinazolinones (represented by icFSP1) as potent FSP1 inhibitors. We show that icFSP1, unlike iFSP1, the first described on-target FSP1 inhibitor(5), does not competitively inhibit FSP1 enzyme activity, but instead triggers subcellular relocalization of FSP1 from the membrane and FSP1 condensation before ferroptosis induction, in synergism with GPX4 inhibition. icFSP1-induced FSP1 condensates show droplet-like properties consistent with phase separation, an emerging and widespread mechanism to modulate biological activity(7). N-terminal myristoylation, distinct amino acid residues and intrinsically disordered, low-complexity regions in FSP1 were identified to be essential for FSP1-dependent phase separation in cells and in vitro. We further demonstrate that icFSP1 impairs tumour growth and induces FSP1 condensates in tumours in vivo. Hence, our results suggest that icFSP1 exhibits a unique mechanism of action and synergizes with ferroptosis-inducing agents to potentiate the ferroptotic cell death response, thus providing a rationale for targeting FSP1-dependent phase separation as an efficient anti-cancer therapy. Nature Publishing Group UK 2023-06-28 2023 /pmc/articles/PMC10338336/ /pubmed/37380771 http://dx.doi.org/10.1038/s41586-023-06255-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Nakamura, Toshitaka Hipp, Clara Santos Dias Mourão, André Borggräfe, Jan Aldrovandi, Maceler Henkelmann, Bernhard Wanninger, Jonas Mishima, Eikan Lytton, Elena Emler, David Proneth, Bettina Sattler, Michael Conrad, Marcus Phase separation of FSP1 promotes ferroptosis |
title | Phase separation of FSP1 promotes ferroptosis |
title_full | Phase separation of FSP1 promotes ferroptosis |
title_fullStr | Phase separation of FSP1 promotes ferroptosis |
title_full_unstemmed | Phase separation of FSP1 promotes ferroptosis |
title_short | Phase separation of FSP1 promotes ferroptosis |
title_sort | phase separation of fsp1 promotes ferroptosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338336/ https://www.ncbi.nlm.nih.gov/pubmed/37380771 http://dx.doi.org/10.1038/s41586-023-06255-6 |
work_keys_str_mv | AT nakamuratoshitaka phaseseparationoffsp1promotesferroptosis AT hippclara phaseseparationoffsp1promotesferroptosis AT santosdiasmouraoandre phaseseparationoffsp1promotesferroptosis AT borggrafejan phaseseparationoffsp1promotesferroptosis AT aldrovandimaceler phaseseparationoffsp1promotesferroptosis AT henkelmannbernhard phaseseparationoffsp1promotesferroptosis AT wanningerjonas phaseseparationoffsp1promotesferroptosis AT mishimaeikan phaseseparationoffsp1promotesferroptosis AT lyttonelena phaseseparationoffsp1promotesferroptosis AT emlerdavid phaseseparationoffsp1promotesferroptosis AT pronethbettina phaseseparationoffsp1promotesferroptosis AT sattlermichael phaseseparationoffsp1promotesferroptosis AT conradmarcus phaseseparationoffsp1promotesferroptosis |